| Website | bioenvision.com |
| Category | BioTech |
| Phone | 212-750-6700 |
| Employees | |
| Founded | 1996 |
| TOTAL | $7.41M |
| FUNDING TOTAL | $7.41M |
| Venture Round, 4/07 SCO Capital Partners Perseus Aisling Capital | $7.41M |
Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.
